Why the study?
Coronary heart disease is a leading cause of death and people with cardiometabolic disorders are at higher risk, prompting evaluation of retinal images for CHD risk estimation.
Does retinal image analysis using the ARIA algorithm accurately estimate CHD risk in people with cardiometabolic disorders?
Does retinal image analysis using the ARIA algorithm accurately estimate CHD risk in people with cardiometabolic disorders?
Retinal image analysis using the ARIA algorithm and machine learning provides high accuracy for estimating CHD risk in patients with cardiometabolic disorders.
May aid noninvasive CHD risk estimation in cardiometabolic disorders; leaves open prospective validation before clinical adoption.
Background: Coronary heart disease (CHD) is the leading cause of death worldwide, constituting a growing health and social burden. People with cardiometabolic disorders are more likely to develop CHD. Retinal image analysis is a novel and noninvasive method to assess microvascular function. We aim to investigate whether retinal images can be used for CHD risk estimation for people with cardiometabolic disorders. Methods: We have conducted a case–control study at Shenzhen Traditional Chinese Medicine Hospital, where 188 CHD patients and 128 controls with cardiometabolic disorders were recruited. Retinal images were captured within two weeks of admission. The retinal characteristics were estimated by the automatic retinal imaging analysis (ARIA) algorithm. Risk estimation models were established for CHD patients using machine learning approaches. We divided CHD patients into a diabetes group and a non-diabetes group for sensitivity analysis. A ten-fold cross-validation method was used to validate the results. Results: The sensitivity and specificity were 81.3% and 88.3%, respectively, with an accuracy of 85.4% for CHD risk estimation. The risk estimation model for CHD with diabetes performed better than the model for CHD without diabetes. Conclusions: The ARIA algorithm can be used as a risk assessment tool for CHD for people with cardiometabolic disorders.
No takes yet. Share an insight, caveat, or question.
Qu et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: